Highlights China Grand Pha.and Healthcare Hld. Ltd. Hong Kong S.E.

Equities

0512

BMG210A71198

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Grand Pharmaceutical Group Enrolls First Patient in Phase 1 Study for Myopia Eye Drops in China	12/06	MT
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment	11/06	CI
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	04/06	CI
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	29/04	MT
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	27/03	CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	25/03	MT
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	24/03	CI
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	20/03	CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	07/03	CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	08/02	MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	16/01	MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	27/12	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	27/12	CI
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	22/12	MT
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	13/12	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01	02/11	CI
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing	24/23/24	CI
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint	13/23/13	CI
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently	17/23/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights China Grand Pha.and Healthcare Hld. Ltd. Hong Kong S.E.

Equities

0512

BMG210A71198

Highlights

Filters